TITLE

Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen

AUTHOR(S)
Bright, Jennifer D.; Schultz, heather N.; Byrne, Jennifer A.; Bright, Robert K.
PUB. DATE
July 2013
SOURCE
OncoImmunology;Jul2013, Vol. 2 Issue 7, pe25049-1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tumor protein D52 (D52) is constitutively expressed in healthy tissues and overexpressed in multiple cancers, including (but not limited to) breast, prostate and ovarian carcinomas. although the normal functions of D52 are unknown, it is clear that increased D52 expression levels not only stimulate cell proliferation and metastasis, but also correlate with poor prognosis in a subset of breast cancer patients. The murine orthologs of D52 (mD52) shares 86% identity with its human counterpart (hD52) and mirrors hD52 expression patterns. The forced overexpression of mD52 induces anchorage-independent growth in vitro and promotes tumor formation as well as spontaneous metastasis in vivo. We have previously reported that the intramuscular administration of recombinant mD52 elicits immune responses capable of rejecting a challenge with tumor cells and preventing spontaneous metastasis only in 50% of mice. We hypothesized that mechanisms of peripheral tolerance dampen immune responses against mD52, thus limiting the protective efects of vaccination. To test this hypothesis, mice were depleted of cD25+ regulatory T cells (Tregs) and subcutaneously immunized with mD52 prior to a tumor challenge. The subcutaneous immunization failed to induce protective antitumor immunity unless accompanied by Treg depletion, which resulted in a rate of protection of 70% as compared with < 10% achieved in immunized Treg-repleted mice. The depletion of cD25+ Tregs did not inhibit the induction of immunological memory, since mice rejected a second tumor challenge administered weeks later. These data indicate that the induction of antitumor immune responses and immunologic memory by an mD52-based subcutaneous vaccination requires the depletion of cD25+ Tregs.
ACCESSION #
89978377

 

Related Articles

  • CTLA-4: new insights into its biological function and use in tumor immunotherapy. Egen, Jackson G.; Kuhns, Michael S.; Allison, James P. // Nature Immunology;Jul2002, Vol. 3 Issue 7, p611 

    The discovery of multiple costimulatory cell surface molecules that influence the course oft cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory...

  • Elimination of CD4+ T Cells Enhances Anti-Tumor Effect of Locally Secreted Interleukin-12 on B16 Mouse Melanoma and Induces Vitiligo-Like Coat Color Alteration. Nagai, Hiroshi; Hara, Isao; Horikawa, Tatsuya; Oka, Masahiro; Kamidono, Sadao; Ichihashi, Masamitsu // Journal of Investigative Dermatology;Dec2000, Vol. 115 Issue 6, p1059 

    Summary CD4+ T cells have been reported to suppress immunity against cancer in certain animal models. In this study, we investigated the role of CD4+ T cells in the anti-tumor immune response when interleukin-12-producing melanoma cells are inoculated in mice. We found that...

  • Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles. VIATTE, SEBASTIEN; ALVES, PEDRO M.; ROMERO, PEDRO // Immunology & Cell Biology;Jun2006, Vol. 84 Issue 3, p318 

    One of the challenges of tumour immunology remains the identification of strongly immunogenic tumour antigens for vaccination. Reverse immunology, that is, the procedure to predict and identify immunogenic peptides from the sequence of a gene product of interest, has been postulated to be a...

  • DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA. devaraj, Kalpana; Gillison, Maura L.; Wu, T.-C. // Critical Reviews in Oral Biology & Medicine;Sep2003, Vol. 14 Issue 5, p345 

    High-risk genotypes of the human papillomavirus (HPV), particularly HPV type 16, are found in a distinct subset of head and neck squamous cell carcinomas (HNSCC). Thus, these HPV-associated HNSCC may be prevented or treated by vaccines designed to induce appropriate HPV virus-specific immune...

  • Durable Remission of Renal Cell Carcinoma in Conjuncture with Graft versus Host Disease following Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion: Rule or Exception? van Bergen, Cornelis A. M.; Verdegaal, Elisabeth M. E.; Honders, M. Wilhelmina; Hoogstraten, Conny; Steijn-van Tol, A. Q. M. Jeanne; de Quartel, Linda; de Jong, Joan; Meyering, Maaike; Falkenburg, J. H. Frederik; Griffioen, Marieke; Osanto, Susanne // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Allogeneic stem cell transplantation (alloSCT) followed by donor lymphocyte infusion (DLI) can be applied as immunotherapeutic intervention to treat malignant diseases. Here, we describe a patient with progressive metastatic clear cell renal cell carcinoma (RCC) who was treated with T cell...

  • Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Bilusic, Marijo; Heery, Christopher; Arlen, Philip; Rauckhorst, Myrna; Apelian, David; Tsang, Kwong; Tucker, Jo; Jochems, Caroline; Schlom, Jeffrey; Gulley, James; Madan, Ravi // Cancer Immunology, Immunotherapy;Mar2014, Vol. 63 Issue 3, p225 

    Yeast-CEA (GI-6207) is a therapeutic cancer vaccine genetically modified to express recombinant carcinoembryonic antigen (CEA) protein, using heat-killed yeast ( Saccharomyces cerevisiae) as a vector. In preclinical studies, yeast-CEA induced a strong immune response to CEA and antitumor...

  • Tumour immunology: Tumours support the T cell response. Irving, Karen // Nature Reviews Immunology;Sep2010, Vol. 10 Issue 9, p617 

    The article reports on the study conducted by E. D. Thompson, and colleagues which shows that tumour masses support naive T cells infiltration, activation, and effector differentiation. It employs mice as research models and determines which mediates the T cell activation, whether the direct...

  • How do CD4+T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Werner Haabeth, Ole Audun; Aune Tveita, Anders; Fauskanger, Marte; Schjesvold, Fredrik; Berg Lorvik, Kristina; Hofgaard, Peter O.; Omholt, Hilde; Munthe, Ludvig A.; Dembic, Zlatko; Corthay, Alexandre; Bogen, Bjarne // Frontiers in Immunology;Apr2014, Vol. 5, p1 

    CD4+T cells contribute to tumor eradication, even in the absence of CD8+T cells. Cytotoxic CD4+ T cells can directly kill MHC class II positive tumor cells. More surprisingly, CD4+ T cells can indirectly eliminate tumor cells that lack MHC class II expression. Here, we review the mechanisms of...

  • Therapeutic Monoclonal Antibodies: Current Perspectives and Applications for the Treatment of Head and Neck Cancer. Blein, Stanislas; Sam Hou // International Journal of Head & Neck Surgery;May-Aug2011, Vol. 2 Issue 2, p87 

    Over the past two decades, monoclonal antibodies have emerged as a versatile class of therapeutics with unique properties. More than 30 therapeutic antibodies are now approved in the United States and European Union, with numerous candidates filling the preclinical and clinical pipeline of every...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics